Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Paediatric labelling requirements. Implications for pharmacokinetic studies

J T Wilson1, G L Kearns, D Murphy

  • 1Department of Pharmacology, Louisiana State University Medical Center, Shreveport.

Clinical Pharmacokinetics
|April 1, 1994
PubMed
Summary

New FDA regulations encourage pediatric drug studies, making clinical trials more feasible. Population-based pharmacokinetic and pharmacodynamic analyses are crucial for individualizing pediatric drug therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Human IgG antibody profiles differentiate between symptomatic patients with and without colorectal cancer.

Gut·2009
Same author

The functional outcome and recovery of patients admitted to an intensive care unit following drug overdose: a follow-up study.

Anaesthesia and intensive care·2009
Same author

Traveller health: prevalence of diabetes, pre diabetes and the metabolic syndrome.

Irish medical journal·2009
Same author

The prevalence and distribution of Mycobacterium bovis infection in European badgers (Meles meles) as determined by enhanced post mortem examination and bacteriological culture.

Research in veterinary science·2009
Same author

Effects of estrogen therapy on age-related differences in gray matter concentration.

Climacteric : the journal of the International Menopause Society·2009
Same author

Neuroleptics in the treatment of aggressive challenging behaviour for people with intellectual disabilities: a randomised controlled trial (NACHBID).

Health technology assessment (Winchester, England)·2009

Area of Science:

  • Pharmacology
  • Clinical Trials
  • Drug Development

Background:

  • The US Food and Drug Administration (FDA) has proposed new regulations to facilitate drug labeling for pediatric use.
  • This encourages studies of drugs in pediatric populations, addressing ethical and technical trial challenges.

Purpose of the Study:

  • To highlight the importance of pediatric pharmacokinetic studies in drug development.
  • To emphasize the role of population-based methods in generating robust data for pediatric drug use.

Main Methods:

  • Review of FDA's proposed labeling regulations.
  • Discussion of population-based pharmacokinetic and pharmacodynamic data analysis techniques.
  • Consideration of ethical and technological factors in pediatric clinical trials.

Related Experiment Videos

Main Results:

  • The FDA's proposed regulations may increase the feasibility and ethical considerations of pediatric clinical trials.
  • Population-based methods offer a robust approach for analyzing pediatric pharmacokinetic and pharmacodynamic data.
  • Individualized therapy for pediatric patients requires specific data from infants and children.

Conclusions:

  • Paediatric pharmacokinetic studies are vital for safe and effective drug use in children.
  • Population-based analytical techniques are essential for creating comprehensive pediatric drug databases.
  • Further research and funding, like that from the NIH, will advance pediatric clinical trials and drug labeling.